Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial

Dugel, Pravin U.; Tolentino, Michael; Feiner, Leonard; Kozma, Petra; Leroy, Annick

doi:10.1016/j.ophtha.2016.06.043

Cited by 88 publications

(139 citation statements)

References 24 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Ocriplasmin is a first-in-class drug and its safety profile is nowhere near completion. The primary endpoint of the first and main studies was changes on OCT, although these do not always go hand in hand with visual improvement or decline and thus more studies are needed focusing also on visual gain [7,8,10].…”

Section: Discussionmentioning

confidence: 99%

Effect of intravitreal C3F8 gas in patients with vitreomacular traction

Haas

Mayer

Wackernagel

2017

Spektrum Augenheilkd.

View full text Add to dashboard Cite

SummaryBackground We aimed to assess the efficacy of a single intravitreal perfluoropropane (C3F8) gas injection for the treatment of vitreomacular traction with or without a macular hole. Methods In this retrospective case series, seven eyes of six patients with symptomatic vitreomacular traction documented on optical coherence tomography, one with a macular hole additionally, received a single intravitreal C3F8 gas injection of up to 0.3 ml. The primary endpoint was vitreomacular traction release at 1 month after injection. Secondary endpoints included resolution of vitreomacular adhesion within 6 months, nonsurgical closure of macular holes, and change in central foveal thickness and best-corrected visual acuity. Results Overall, on optical coherence tomography, six of seven eyes (85.7%) had release of vitreomacular traction during the entire study duration: three within 1 month of injection and the other three within 6 months. Of the latter group, two of the three eyes showed a concurrent epiretinal membrane and one concurrent diabetic retino-and maculopathy. The patient with a macular hole had resolution of vitreomacular traction within 1 month but had to undergo vitrectomy because of nonclosure of the macular hole. Associated adverse events were macular edema with a consequent lamellar hole after injection in one patient, and another patient developed retinal detachment. Conclusion Intravitreal C3F8gas injection is an inexpensive and promising minimally invasive option for the treatment of symptomatic and persistent vitreo-

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of intravitreal C3F8 gas in patients with vitreomacular traction

Haas

Mayer

Wackernagel

2017

Spektrum Augenheilkd.

View full text Add to dashboard Cite

show abstract

“…Macular Hole (OASIS) trial was designed by the drug manufacturer to evaluate the long-term efficacy and safety profile of ocriplasmin for the treatment of symptomatic VMA/VMT, including FTMH. 171 This trial demonstrated the long-term efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA compared with previous phase III trials.…”

Section: The Ocriplasmin For Treatment For Symptomatic Vitreomacular mentioning

confidence: 70%

Idiopathic Macular Hole Preferred Practice Pattern®

et al. 2020

View full text Add to dashboard Cite

“…In the recent OASIS multicenter study, ocriplasmin was validated to be of benefit in the treatment of vitreomacular adhesion, including macular hole, even after 2 years of follow-up. The anatomical success of treatment was significantly higher in the treatment group [16] . In a phase III double-blinded trial [6] , there was a nonsurgical resolution of vitreomacular traction in 26.5% of the patients in the ocriplasmin group compared with 10.1% in the placebo group.…”

Section: Discussionmentioning

confidence: 84%

Impact of Preinjection Spectral Domain Optical Coherence Tomography Findings in the Use of Intravitreal Ocriplasmin in a Clinical Setting

Wertheimer¹,

Haritoglou²,

Laubichler³

et al. 2017

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To investigate the impact of spectral domain optical coherence tomography (SD-OCT) morphological predictive markers on visual acuity and outcome using ocriplasmin for macular hole and vitreomacular traction syndrome. Methods: A series of 40 patients in a retrospective study received intravitreal ocriplasmin. The primary endpoint was defined as morphological resolution of vitreomacular traction or closure of a macular hole. We analyzed the impact of pre- and postinjection SD-OCT findings on the outcome and visual acuity. Results: Thirteen of the 40 patients benefited from treatment. Statistical correlation between baseline characteristics and outcome revealed that higher foveal thickness (p = 0.018) and nontractional epiretinal membranes (p = 0.05) resulted in a worse outcome. In treatment success best corrected visual acuity gained was 9 (SD 12) letters and in failure 1 (SD 9) letter. We could not observe an influence of preinjection SD-OCT findings and other factors on visual outcome. Conclusion: We could confirm the therapeutic effect of ocriplasmin injections. SD-OCT morphological factors that influence treatment success and visual acuity were determined.

show abstract

Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial

Cited by 88 publications

References 24 publications

Effect of intravitreal C3F8 gas in patients with vitreomacular traction

Effect of intravitreal C3F8 gas in patients with vitreomacular traction

Idiopathic Macular Hole Preferred Practice Pattern®

Impact of Preinjection Spectral Domain Optical Coherence Tomography Findings in the Use of Intravitreal Ocriplasmin in a Clinical Setting

Contact Info

Product

Resources

About